Health Condition 1: null- Rheumatoid arthritis
Conditions
Interventions
Intervention1: Methotrexate , Sulfasalazine, Hydroxychloroquine: Methotrexate 25mg per week, Sulfasalazine 1 gram twice a day, Hydroxychloroquine 200mg once at night, all in combination for 3 months
I
Sponsors
JIPMER Intramural fund
Eligibility
Inclusion criteria
Inclusion criteria: 1.satisfying ACR-EULAR criteria for Rheumatoid arthritis 2.Polyarthritis ( >4 joints) 3.Disease duration of less than 2 years 4.DMARD naïve patients 5.Patients with moderate to severe disease activity (DAS28 >3.2)
Exclusion criteria
Exclusion criteria: 1.End stage disease (deformed fixed joints) 2.Patients with vasculitis, extra-articular features like interstitial lung disease 3.Contraindications to DMARD therapy (Chronic Alcoholism, Chronic liver disease, Evidence of acute/chronic infection, Chronic kidney disease, Patients with leucopenia ( AST/ALT >2Ã? upper normal value and creatinine clearance 4.Pregnant, lactating women, patients (both men and women) of reproductive age group unwilling for contraceptive use who have not completed the family
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease activity (state) DAS28 ESRTimepoint: at baseline, 3 months and 6 months | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.Functional ability â?? iHAQ 2.Mean changes over time in: Inflammatory parameters: ESR, hs-CRP 3.Disease activity as per US-7 score and damage by SENS 4.Adverse drug reactionsTimepoint: at baseline , 3 months and 6 months | — |
Countries
India
Contacts
Public ContactDr Vir Singh Negi
Jawaharlal Institute of Postgraduate Medical Education and Research
Outcome results
None listed